The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Consensus and debate in newly diagnosed multiple myeloma: autoSCT, immunotherapy, & MRD
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the key points from a roundtable discussion on newly diagnosed multiple myeloma (NDMM), highlighting a consensus on the role of autologous stem cell transplantation (autoSCT) and the potential of immunotherapies. Dr Zamagni notes that while there is agreement on the utility of measurable residual disease (MRD) testing, there is some debate on how to use MRD results to tailor treatment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.”
